vimarsana.com

Latest Breaking News On - 09058v10 - Page 3 : vimarsana.com

BioCryst Pharmaceuticals, Inc (NASDAQ:BCRX) Receives Consensus Recommendation of Buy from Analysts

Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Free Report) have been assigned a consensus rating of “Buy” from the seven ratings firms that are currently covering the stock, Marketbeat Ratings reports. Seven research analysts have rated the stock with a buy rating. The average 12 month price objective among brokerages that have issued a […]

BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Up 2%

Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Free Report) were up 2% on Wednesday . The stock traded as high as $5.99 and last traded at $5.98. Approximately 127,217 shares changed hands during mid-day trading, a decline of 95% from the average daily volume of 2,795,453 shares. The stock had previously closed at $5.86. […]

BioCryst Pharmaceuticals, Inc (NASDAQ:BCRX) Given Average Recommendation of Buy by Analysts

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Free Report) has been given an average rating of “Buy” by the seven analysts that are presently covering the stock, MarketBeat Ratings reports. Seven investment analysts have rated the stock with a buy rating. The average 12-month price objective among brokerages that have updated their coverage on the stock […]

BioCryst Pharmaceuticals (NASDAQ:BCRX) Hits New 12-Month Low at $6 06

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Free Report) shares reached a new 52-week low on Tuesday . The stock traded as low as $6.06 and last traded at $6.14, with a volume of 73957 shares. The stock had previously closed at $6.15. Wall Street Analysts Forecast Growth Several research firms have recently weighed in on […]

BioCryst Pharmaceuticals, Inc (NASDAQ:BCRX) Receives Average Rating of Buy from Analysts

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Free Report) has been assigned a consensus rating of “Buy” from the seven brokerages that are currently covering the stock, Marketbeat reports. Seven investment analysts have rated the stock with a buy recommendation. The average 12 month price objective among brokers that have issued ratings on the stock in […]

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.